BeOne Medicines (ONC) Current Deferred Revenue (2015 - 2023)

BeOne Medicines (ONC) has reported Current Deferred Revenue for 8 consecutive years, with $159.0 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Current Deferred Revenue fell 2.67% year-over-year to $159.0 million; the TTM figure through Jun 2023 stood at $159.0 million (down 2.67% YoY), while the FY2022 annual figure was $213.9 million, down 28.71% from the prior year.
• Current Deferred Revenue fell to $159.0 million in Q2 2023 per ONC's latest filing, from $185.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $300.0 million in Q4 2021 and bottomed at $17.5 million in Q1 2019.
• Historically, Current Deferred Revenue has averaged $141.4 million across 4 years, with a median of $159.0 million in 2023.
• On a YoY basis, Current Deferred Revenue climbed as much as 156.89% in 2022 and fell as far as 28.71% in 2022.
• BeOne Medicines' Current Deferred Revenue stood at $17.5 million in 2019, then soared by 1613.89% to $300.0 million in 2021, then dropped by 28.71% to $213.9 million in 2022, then decreased by 25.64% to $159.0 million in 2023.
• Business Quant data shows ONC's Current Deferred Revenue at $159.0 million in Q2 2023, $185.5 million in Q1 2023, and $213.9 million in Q4 2022.